[Congressional Record (Bound Edition), Volume 145 (1999), Part 15] [Extensions of Remarks] [Page 22304] [From the U.S. Government Publishing Office, www.gpo.gov]THE HERMELIN BRAIN TUMOR CENTER--NEW HOPE FOR CANCER PATIENTS ______ HON. TOM LANTOS of california in the house of representatives Wednesday, September 22, 1999 Mr. LANTOS. Mr. Speaker, this year in the United States some 20,000 new cases of primary brain tumors will be diagnosed, and more than 100,000 cases of cancer migrating to the brain from a different site will be found. Traditional treatment regimens of surgery, chemotherapy, and radiation have not stopped the natural progression of the disease in far too many cases, and new therapies are desperately needed. Finding new treatments often means years of laboratory investigation, followed by both clinical trials and the examination of results, before such therapies can be deemed successful and made available to patients. Speeding up this process is of vital importance to innumerable cancer patients. With this in mind, friends and family of David B. Hermelin have pledged $10 million to launch a brain tumor research center at Henry Ford Hospital in Detroit. Mr. Speaker, David Hermelin is the United States Ambassador to Norway, and earlier this year he was successfully treated for a brain tumor. Currently, he is undergoing therapy at the Henry Ford Hospital. The funds donated in his name will launch the Hermelin Brain Tumor Center, housed within the Department of Neurosurgery. The center will be directed by Mark L. Rosenblum, M.D., Chair of the Department of Neurosurgery, and by Tom Mikkelsen, M.D., of the Departments of Neurology and Neurosurgery. ``The center at Henry Ford Hospital is now positioned to make a significant impact on this disease,'' said Dr. Rosenblum. ``With state- of-the-art technology for diagnosis and surgery, with continual ability to provide the most advanced surgery and treatments available, and with new discoveries from our research team, we are confident we will be able to change life-threatening brain tumors into a chronic, controllable disease like diabetes.'' The Hermelin Brain Tumor Center will support three main areas of novel investigation to help control brain tumors: (1) antiinvasion therapy (which stops a tumor from invading healthy brain tissues), (2) gene therapy (which uses scientifically engineered viruses which recognize and kill cancer cells), and (3) antiangiogenesis (which stops a tumor from building its network of blood vessels, effectively starving it). In addition, the Center will sponsor annual brain tumor workshops focusing on each of these three areas of research. Brain tumor scientists from around the world will be invited to share their knowledge and compete for a research grant, thus providing new ways to share novel findings and to use these findings to fund research that will bring new treatments to patients in the most rapid possible manner. Mr. Speaker, David Hermelin is an outstanding citizen of our Nation, and as United States Ambassador to Norway, he has made an important contribution to strengthening traditional good relations between our country and Norway. In addition, he is a leading philanthropist who has spearheaded major fund-raising efforts which have garnered millions of dollars for academic, medical, civic, religious and charitable organizations. The Hermelin Brain Tumor Center is a fitting and unique recognition of his generous contributions. I invite my colleagues to join me in honoring Ambassador David Hermelin and recognizing the importance of the Hermelin Brain Tumor Center. ____________________